REAL-WORLD COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB

被引：0
|
作者：
Rogers, K. A. [1 ]
Qureshi, Z. P. [2 ]
Ding, Z. [2 ]
Emond, B. [3 ]
Gogna, P. [3 ]
Lafeuille, M. H. [3 ]
Bokun, A. [2 ]
Fradley, M. [4 ,5 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Hosp Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Thalheimer Ctr Cardiooncol, Philadelphia, PA USA
[5] Hosp Univ Penn, Perelman Sch Med, Div Cardiol, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE70
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [31] Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation
    Fradley, Michael
    Lafeuille, Marie-Helene
    Emond, Bruno
    Crawford, Samuel
    Chen, Naijun
    Volodarsky, Raisa
    Nielsen, Jacqueline
    Srivastava, Bhavini Patel
    [J]. BLOOD, 2022, 140 : 10983 - 10984
  • [32] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    [J]. VALUE IN HEALTH, 2021, 24 : S38 - S38
  • [33] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina P.
    Pinilla-Ibarz, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] COMPARATIVE STUDY OF HEALTHCARE RESOURCE UTILIZATION (HRU) OUTCOMES BETWEEN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB VERSUS NON-IBRUTINIB TREATED PATIENTS
    Nero, D.
    Chung, J.
    Kish, J.
    Nabhan, C.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A414 - A414
  • [35] Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
    Huntington, Scott F.
    Soulos, Pamela R.
    Barr, Paul M.
    Jacobs, Ryan
    Lansigan, Frederick
    Odejide, Oreofe O.
    Schwartzberg, Lee S.
    Davidoff, Amy J.
    Gross, Cary P.
    [J]. BLOOD, 2019, 134
  • [36] Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States
    Seiter, Karen
    Latremouille-Viau, Dominick
    Guerin, Annie
    Ndife, Briana
    Habucky, Karen
    Joseph, George J.
    Pivneva, Irina
    Gagnon-Sanschagrin, Patrick
    Tang, Derek H.
    [J]. BLOOD, 2017, 130
  • [37] Comparing acalabrutinib and ibrutinib in the real world: a study of 2,509 patients with chronic lymphocytic leukemia
    Christofyllakis, K.
    Roeker, L.
    DerSarkissian, M.
    Ryan, K. J.
    Chen, Y.
    Wahlstrom, S. K.
    Hakre, S.
    Yu, L.
    Guo, H.
    Mato, A. R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 35 - 36
  • [38] Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie J.
    Chen, Yan
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    [J]. BLOOD, 2022, 140 : 4156 - 4158
  • [39] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
    Jacobs, Ryan W.
    Teschemaker, Anna
    Hakre, Shweta
    Tian, Hongping
    Pyrih, Nick
    Wahlstrom, Svea K.
    Cui, Lianzhou
    [J]. BLOOD, 2023, 142
  • [40] Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.
    Rogers, Kerry Anne
    Emond, Bruno
    Manceur, Ameur M.
    Kinkead, Frederic
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345